达格列净联合甘精胰岛素治疗2型糖尿病临床研究

Clinical Study of Daggligin Combined with Insulin Glargine in the Treatment of Type 2 Diabetes

目的探讨达格列净联合甘精胰岛素治疗2型糖尿病的临床疗效。方法分别选取医院2021年10月至12月和2022年1月至3月收治的2型糖尿病患者各34例,作为对照组和观察组。两组患者均给予甘精胰岛素治疗,观察组患者加用达格列净治疗。两组患者均连续治疗30 d。结果观察组患者的总有效率为94.12%,显著高于对照组的76.47%(P<0.05)。治疗后,观察组患者的血糖及血脂水平均显著低于对照组(P<0.05)。结论达格列净联合甘精胰岛素治疗2型糖尿病的临床疗效良好,可显著改善患者的糖脂代谢。

Objective To investigate the clinical efficacy of daggligin combined with insulin glargine in the treatment of type 2 diabetes.Methods A total of 34 patients with type 2 diabetes admitted to the hospital from October to December 2021 were selected as the control group,and those from January to March 2022 were selected as the observation group.Both groups were treated with insulin glargine,while the observation group received additional treatment with dapagliflozin.Both groups were treated continuously for 30 d.Results The total effective rate in the observation group was 94.12%,which was significantly higher than 76.47% in the control group(P<0.05).After treatment,the blood glucose and lipid levels in the observation group were significantly lower than those in the control group(P<0.05).Conclusion Daggligin combined with insulin glargine has a good clinical effect in the treatment of type 2 diabetes,which can significantly improve the glucose and lipid metabolism of patients.